In July 2011, FDA approved indacaterol, Novartis's new once-daily long-acting beta agonist, for the treatment of chronic obstructive pulmonary disease.
Big bucks riding on FDA's little dosing…
In July 2011, FDA approved indacaterol, Novartis's new once-daily long-acting beta agonist, for the treatment of chronic obstructive pulmonary disease.